## Abstract There is increasing demand for mononuclear cell (MNC) harvests not only for PBPC but also for immune therapies using dendritic cells and donor lymphocytes. We determined the collection efficiencies (CE) of various MNC subpopulations during CD34^+^ cell harvests using a Fenwal CS 3000 Pl
CD34+ collection efficiency as a function of blood volumes processed in pediatric autologous peripheral blood stem cell collection
β Scribed by Leonid Dubrovsky; Edward C.C. Wong; Evelio Perez-Albuerne; Brett Loechelt; Naynesh Kamani; Jane Sande; Kathy Mintz; Wendy Paul; Naomi L.C. Luban; Brian R. Rood; Terry Fry
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 226 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Purpose:
To characterize the relationship between CD34^+^ collection efficiency and blood volumes processed in pediatric patients undergoing autologous peripheral blood stem cell (PBSC) collection.
Methods:
Retrospective 8βyear (2001β2009) study of pediatric patients (n = 79) with neuroblastoma and central nervous system (CNS) tumors undergoing first day of autologous PBSC harvest using MNC program on the COBE Spectra (Caridian BCT, Lakewood, CO) was performed. Patients undergoing 0 to 2.9 BV (standard volume), 3 to 6 BV (large volume), and greater than 6 BV (ultra large volume) harvests were evaluated for CD34^+^ collection efficiency, diagnosis (neuroblastoma vs. nonneuroblastoma), disease type (primary vs. relapse), mobilization regimen, granulocyte colony stimulating factor (GCSF) dose, and apheresis complications.
Results:
CD34^+^ collection efficiencies (CE) for neuroblastoma patients were 67%, 50%, and 53% for standard (n = 14), large (n = 9), and ultra large (n = 5) volume harvests, respectively. Similarly, patients with nonneuroblastoma diagnoses had CD34^+^ CE of 63%, 55%, and 65% for low (n = 19), large (n = 27), and ultra large (n = 5) volume harvests, respectively. Weight, granulocyte colony stimulating factor (GβCSF) stimulation, type of mobilization, and apheresis complications (normalized by run time) were similar between the standard, large, and ultra large volume groups in patients with either neuroblastoma or nonneuroblastoma diagnoses.
Conclusions:
CD34^+^ collection efficiency in pediatric autologous PBSC collection on the first day of harvest does not decrease with higher numbers of blood volumes processed in patients with either neuroblastoma or nonneuroblastoma primary disease. These results indirectly indicate bone marrow CD34^+^ cell mobilization occurs with longer apheresis procedures in pediatric patients. J. Clin. Apheresis, 2011. Β© 2011 WileyβLiss, Inc.
π SIMILAR VOLUMES
The number of CD34+ cells in peripheral blood (PB) is a guide to the optimal timing to harvest peripheral blood progenitor cells (PBPC). The objective was to determine the number of CD34+ cells in PB that allows achieving a final apheresis product containing 1.5 β’ 10 6 CD34+ cells/kg, performing up
## Abstract We previously showed that at least 5/mm^3^ hematopoietic progenitor cells (HPCs) could be used as a marker for initiating autologous blood stem cell collection (ABSCC). However, the timing of efficient ABSCC following mobilization is still to be determined. We conducted a prospective, r
In this report we analyzed sixty leukapheresis procedures on 35 patients with a new protocol for the Fresenius AS 104. Yields and efficiencies for MNC, CD 34+ cells, and CFU-GM indicate that the new protocol is able to collect large quantities of hemopoietic progenitors. Procedures were performed pr
## Abstract There have only been a few reports and limited performance of peripheral blood stem cell (PBSC) collection in very small children weighing less than 10 kg. In this study, we intended to evaluate the safety and yield of PBSC collection, with the efficacy of PBSC transplantation (PBSCT) i
Leukapheresis demands patient's compliance and adequate vascular accesses, which can require invasive methods in very small children whose treatment protocol includes hemopoietic stem cell collection for myeloablative chemotherapy and stem cell rescue. Since 1998, at the Istituto Nazionale Tumori of